Content of Reports. Reports shall include at least the following on a Licensed Product-by-Licensed Product, country-by-country, and Sublicense-by-Sublicense basis:
Content of Reports. The Compliance Monitor’s reports shall include non-privileged information regarding the following during the relevant time-periods preceding the report:
Content of Reports. Any Reports provided pursuant to Section 3.3.1 will include at least information regarding: (a) completed activities with respect to the Development of Acquired Antibodies and Products as well as the anticipated Development activities planned in the subsequent [***]; (b) activities with respect to the milestone events described in Section 5.2 including, when such milestone events are expected to be achieved and whether or not such Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. Confidential Treatment Requested by Kiniksa Pharmaceuticals, Ltd. milestone events have been achieved; (c) an updated list of the Acquired Patent Rights or Kiniksa Patent Rights; and (d) the anticipated date and actual date, as applicable, of the First Commercial Sale of each Product in each country of the Territory; provided, however, that after a Product receives Marketing Authorization, the information required in (a) will only need to be provided [***] and will include planned activities for the subsequent [***]. In addition, in order to enable Biogen to prepare its quarterly and annual public disclosures regarding Biogen’s results of operations, on a Product- by-Product basis, upon the earlier of (i) [***] year prior to the anticipated First Commercial Sale of such Product in any country in the Territory, or (ii) the date of Kiniksa’s submission of a Regulatory Filing for a Product in such country, and on a [***] basis thereafter, Kiniksa shall prepare a commercialization report, which report shall include a timeline for achieving First Commercial Sale, a non-binding [***] good faith rolling forecast of Gross Sales and Net Sales of Products in the Field in the Territory, broken down by Calendar Quarters (such forecast, an “Annual [[***]]”). Thereafter, Kiniksa shall provide to Biogen an updated Annual [***] each Calendar Year of the Term.
Content of Reports. 6.3 The progress report must include: status of the project to date, against the project overview and project details contained in the Application; a summary of income received (including details of Co-funding) and expenditure incurred for the Project to date, compared to the Project budget set out in the Application. Any variances will be explained; plans for the next reporting period; any problems arising or expected to arise with the Project or this Agreement (including any delays or expected delays in delivering the projects); and any other information requested by the Ministry.
Content of Reports. 6.3 The progress report must include:
Content of Reports. Each Annual Mileage Report shall report EV miles driven for the periods set forth above. The report shall also describe any major repairs or modifications, malfunctions, and/or replacement of the EV(s) during the year.
Content of Reports. Each Report provided pursuant to Section 3.3.1 will include at least information regarding: (a) completed activities with respect to the Development of Compounds and Products as well as the anticipated Development activities planned in the subsequent [***]; and (b) the anticipated date and actual date, as applicable, of the First Commercial Sale of each Product in each of [***] and [***].
Content of Reports. Each report delivered by Licensee to Symphony shall contain in reasonable detail the calculation of the royalties payable to Symphony for the immediately preceding calendar quarter, including at least the following information:
Content of Reports. Reports will be prepared in a clear and concise manner. When preparing reports, staff will focus on the key information that is required by Council to make effective decisions. Report information will be presented within the report in a fashion that clearly assists Council in the decision making process. Historical information leading up to the staff recommendation will be summarized in the report as opposed to attaching previous reports and studies already dealt with by Council. Reports from Departments must be received by the Clerk one (1) week prior to the next Council meeting.
Content of Reports. (i) Each report delivered by Haemonetics to CoraMed shall contain at least the following information for the immediately preceding Haemonetics fiscal quarter:
